Axia Pharmaceuticals (Fusion IV Pharmaceuticals Inc.), Los Angeles, CA
Is Axia Pharmaceuticals (Fusion IV Pharmaceuticals Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.
Does Axia Pharmaceuticals (Fusion IV Pharmaceuticals Inc.) hold a California pharmacy license?
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.
Has Axia Pharmaceuticals (Fusion IV Pharmaceuticals Inc.) had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 2 Form 483s (Dec 20, 2019 and Mar 13, 2020) for Axia Pharmaceuticals (Fusion IV Pharmaceuticals Inc.). State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists 2 actions: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended” dated Oct 25, 2019, case AC 6371 on license PHY 53726 and “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended” dated Oct 25, 2019, case AC 6371 on license LSC 100855.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Fusion IV Pharmaceuticals Inc.; Axia Pharmaceuticals
- Location
- Los Angeles, CA
- Type as FDA labels it
- 503A
- FDA’s note
- De-registered as an Outsourcing Facility
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 13, 2020
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 9 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Fusion IV Pharmaceuticals Inc. (dba Axia Pharmaceuticals), a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Mar 13, 2020 | Amended Form 483 | Amended 483 Issued 03/13/2020 | FDA copy (archived) |
| Dec 20, 2019 | Form 483 | 483 Issued 12/20/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Dec 2, 2019 to Dec 20, 2019: 9 observations
- Firm on the cover
- Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical, 1990 Westwood Blvd Ste 135, Los Angeles, CA 90025-4650
- FEI number
- 3013341563
- Establishment type on the cover
- Producer o f Sterile Drug Products
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition.
Specifically,
A.
On 12/2/2019, I observed <Redacted B4> laminar flow bench <Redacted B4> with yellow staining on the inside of the ISO-5 laminar flow workstation on the HEPA grid. Aseptic filling of drug products occurs in this LFW. The firm could not provide documentation of the last batches of drug product produced in this laminar flow hood.
B. On 12/2/2019, I observed yellow peeling tape on the aseptic worksurface inside of ISO-5 laminar flow wokstations; <Redacted B4> The tape was fraying and half of the yellow tape line was off. The line was being used as a line of demarcation for the aseptic operators. On 12/3/19, Methylprednisolone Acetate lot 12022019+53297 was being filled and <Redacted B4>.
C. On 12/2/2019, I observed a black plastic tube inside the ISO-5 Laminar flow <Redacted B4> station acting as a particle counter. The black plastic tubing had double sided tape around the top which was frayed. On 12/3/19, Methylprednisolone Acetate lot 12022019+53297 was being filled and <Redacted B4> in this LFW.
- in this LFW.
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically,
A.
Observed on 12/3/2019, during the aseptic processing of Methylpredinsolone Acetate batch 12022019+53297, technician dispensed <Redacted B4> from the <Redacted B4> bag onto the table top of the laminar flow workstation and use <Redacted B4> each vial (Theoretical yield <Redacted B4> unit vials). Your firm is not following your standard operating procedure document number 4.71 titled, "Aseptic Processing Requirements and Technique" which reads in section 7 .1.10, "Compounding personnel shall not use a gloved hand to touch any product contact surfaces, but should use appropriately sterilized utensils ( e.g., forceps), as needed."
B.
Observed on 12/11/2019 in the ISO 5 aseptic filling room, aseptic filling operator performed <Redacted B4> interventions during the <Redacted B4> filling of Glutathione batch 12102019+53365 without routinely sanitizing hands. ...
Observation 3
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A.
Deviation DEV-2018-002 investigation report details a sterility failure for five drug lots. Your firm invalidated the initial sterility failure without adequate justification to support the probable root cause of analytical lab error and noted no recall was necessary due to no patients had reported adverse events. Furthermore, the investigation did not identify the organisms which caused the contamination to the genus or species level or perform a gram stain per the OOS.
invalidated the initial sterility failme without adequate justification to support the probable root cause of analytical lab error and noted no recall was necessary due to no patients had reported adverse events. Fmthermore, the investigation did not identify the organisms which caused the contamination to the genus or species level or perform a gram stain per the OOS. The following are the drug product batches:
Alprostadil 40mcg/Papaverine 30mg/Phentolamine 2 mg; batch lot 02052018+48999 ...
Observation 4
Employees are not given training in the particular operations they perform as part of their function, current good manufacturing practices and written procedures required by current good manufacturing practice regulations.
Specifically,
A.
Quality Control technician (initials <Redacted B4> performing the sterility testing and the endotoxin testing for finished drug products has no documented training for conducting the QC sterility and endotoxin tests or general current good manufacturing practice training or current good documentation practice training. Since the QCs technician hire date of <Redacted B4> the following analysis have been completed by this technician: <Redacted B4> finished drug product lots ran using the <Redacted B4> sterility test method <Redacted B4> finished drug product lots using the <Redacted B4> sterility <Redacted B4> samples ran for endotoxin testing of the finished drug products
B. ...
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform to appropriate standards of identity, strength, quality and purity.
Specifically ,
A. Growth Promotion testing of the <Redacted B4> used in the Aseptic Process Simulations are challenged with only two organisms; Bacillus subtilis and Candida Albicans. The testing of only two organisms does not demonstrate the media can support growth of a wide range of microorganisms. Your firm is not following the Policy on Aseptic Process Simulations as stated in SOP 4.72 section 8.4.8 which states the selection of 5 microorganisms.
B. Your firm has not performed an antimicrobial effectiveness study to verify that the preservative system is effective and protects the product over its shelf life under expected conditions of use. For example, the following drug stock solutions have a shelf life of six months and contain a preservative. You have not verified through antimicrobial effectiveness studies the content of the preservative. In addition, stability studies have not been provided to show the drug product is stable in its container. ...
Observation 6
The quality control unit lacks authority to fully investigate errors that have occurred.
Specifically,
A.
Your firm failed to perform investigations into "Positive" sterility results as outlined in SOP 5.30, titled, Testing of Sterile Preparations section 8.3 .1.1. and SOP 5.54, "Investigating an Out of Specification" section 7.1.
1. Triamcinolone Acetonide 40mg/ml (Preservative Free) lot number 08272019+52841 culture result was "Positive" for media bottle <Redacted B4> utilizing the <Redacted B4> sterility test method. There was no subculture or gram staining performed. There was no out of specification investigation or deviation performed. The lot was distributed to <Redacted B4> office orders.
B.
You r firm failed to perform complaint investigations as outlined in SOP 5.51, Handling of Customer Complaints and Adverse Drug Reactions.
1. Complaint number CR 2018-004 dated November 27, 2018 on the complaint log reads a patient had went into the hospital for sepsis after injection of Testosterone cypionate lot number 09182018+50532. The log details a review of the batch record, release testing and if there were other complaints on this lot. ...
Observation 7
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A.
Your firm has failed to document the electronic review of pressure differential monitoring to ensure during production that pressure differentials are maintained in the ISO-5, ISO-6, ISO-7 and ISO-8 clean rooms during production. SOP 7.13 titled, "Automated EM" section 9.4 requires Quality Unit to document the EM results.
B.
Your firm has failed to investigate the environmental monitoring action limit observed for active viable air sampled in the ISO 5 filler room, location <Redacted B4> recovered. Action limit is <Redacted B4> Your firm did not follow SOP 7 .11 titled, Environmental Monitoring which requires as investigation to assess product impact when applicable.
Observation 8
Examination of packaging and labeling materials for suitability and correctness before packaging operations is not documented in the batch production records.
Specifically,
On 12/5/19, I observed the potential for label mix-ups when labeling of small batches were performed in the filling clean room suite conducted on a table with 5 different drug product lots. The aseptic filling operator had just completed <Redacted B4> a small batch. He then placed 5 small drug batches on the table each batch had approximately <Redacted B4> vials. The lots were: Alprostadil 150 mcg/ml lot 12042019+53331 Papaverine HCL/Phentolamine mesylate 60mg/40mg/ml lot 12042019+53329 Alprostadil/Papaverine HCL/Phentolamine mesylate/ Atropine l 8mcg/l .8mg/0.2mg/0.2mg/ml lot 12042019+53327 Alprostadil/Papaverine HCL/Phentolamine mesylate/ Atropine 40mcg/25mg/0.5mg/0. lmg/ml lot 12042019+53325 Alprostadil/Papaverine HCL/Phentolamine mesylate/ Atropine 60mcg/30mg/2mg/0.15mg/ml lot 12042019+53323 The labels were issued without documentation, batch record or verification of the lot number by Quality Unit. ...
Observation 9
Specifically,
A.
You have not completed method suitability for the <Redacted B4> sterility testing Method Validation document V AL-16-001 for your drug products tested with this sterility test method. Validation Protocol Deviation Report #2 lists test procedures which did not meet the acceptance criteria. Your Quality Unit has not reviewed and summarized the validation data and signed as Reviewed and Approved by.
B.
You have not completed the method suitability for the endotoxin testing using <Redacted B4> Assay <Redacted B4> for all drug products. Currently, only three drug products have completed method suitability.
State board of pharmacy records
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Oct 25, 2019: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended.”, license PHY 53726, case AC 6371, Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical, Los Angeles, CA. Board list
- Oct 25, 2019: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended.”, license LSC 100855, case AC 6371, Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical, Los Angeles, CA. Board list
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.